Pharmacokinetics of linagliptin in subjects with hepatic impairment

AIM: To investigate whether hepatic impairment affects linagliptin pharmacokinetics, pharmacodynamics and tolerability. METHOD: This open label, parallel group, single centre study enrolled patients with mild (n = 8), moderate (n = 9) or severe (n = 8) hepatic impairment and healthy subjects (n = 8)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Graefe-Mody, Ulrike, Rose, Peter, Retlich, Silke, Ring, Arne, Waldhauser, Lisa, Cinca, Rodica, Woerle, Hans-Juergen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Science Inc 2012
Gaiak:
Pharmacokinetics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394131/
https://ncbi.nlm.nih.gov/pubmed/22242621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04173.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak